Intriguingly, ATXN3 acts as an endogenous deubiquitinase of Galectin-9, thereby targeting ATXN3 deletion resulting in the reduced Galectin-9 expression and apoptosis of colon cancer cells. This evidence concerns the gene LGALS9 and malignant colon neoplasm.